A Study of a Psilocybin Analog (CYB003) in Participants With Major Depressive Disorder

A Study of a Psilocybin Analog (CYB003) in Participants With Major Depressive Disorder

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

πŸ“° Weekly newsletter about the psychedelic research

βœ”οΈ Unlimited access to our database and original articles

πŸ–ŠοΈ Add (private) notes and comments to each page

Make an account
Topic Depression
Compound Psilocybin
Status Not yet recruiting
Start date 19 July 2022
End date 23 July 2023
Chance of happening 89%
Phase Phase I Phase II
Design Blinded
Type Interventional
Generation Second
Participants 40
Sex All
Age 21- 55
Therapy No

Trial Details



NCT Number NCT05385783

Sponsors & Collaborators

Cybin
Cybin is a for-profit company that aims to deliver psychedelics (psilocybin) via a sublingual delivery mechanism. The company aims to start clinical trials within the year (2021). It has raised $98 million US.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.
0 Comments
Inline Feedbacks
View all comments